menu
    • menu
    [{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CHO-DG44","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"Aragen Life Sciences \/ Serum Institute of India Private Limited"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Monopar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ Monopar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ Monopar Therapeutics"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Everolimus","moa":"IGF-1R","graph1":"Oncology","graph2":"Phase II","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aragen Life Sciences \/ Boehringer Ingelheim","highestDevelopmentStatusID":"8","companyTruncated":"Aragen Life Sciences \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aragen Life Sciences \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ Clearmind Medicine"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"FAR Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ FAR Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Life Sciences \/ FAR Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Aragen Life Sciences

    Menu

    Aragen Life Sciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : FAR Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegener...

                            Details : Under the collaboration, Aragen will deploy its proven experimental integrated drug discovery (IDD) platform to help FAR advance its small molecule program towards an important milestone in neurodegeneration.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : FAR Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 5-Methoxy-2-Aminoindane

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Clearmind Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With ...

                            Details : In accordance with the agreement, Aragen will do a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 26, 2021

                            Lead Product(s) : 5-Methoxy-2-Aminoindane

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Clearmind Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xentuzumab,Everolimus,Exemestane

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Aragen Announces Expansion of Research Agreement with Boehringer Ingelheim

                            Details : Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.

                            Brand Name : BI 836845

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 29, 2021

                            Lead Product(s) : Xentuzumab,Everolimus,Exemestane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNPR-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Monopar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19

                            Details : The aim of this partnership is to identify the uPRIT with the optimal urokinase plasminogen activator receptor binding profile, enabling selective delivery of a cytotoxic radioisotope to just those aberrantly activated immune cells that produce the cytok...

                            Brand Name : MNPR-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 19, 2020

                            Lead Product(s) : MNPR-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Monopar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Aragen Life Sciences

                            India arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHO-DG44

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Serum Institute of India Private Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Serum Institute and Aragen Bioscience Announce Collaboration on Vaccine Development

                            Details : Under the terms of the collaboration, Aragen is set to provide Serum with high expressing cell lines enabling Serum to quickly move their RapTr™ platform forward into Manufacturing.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 08, 2020

                            Lead Product(s) : CHO-DG44

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Serum Institute of India Private Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth